Probing ligand-binding pockets of the mevalonate pathway enzymes from Streptococcus pneumoniae

Scott T. Lefurgy, Sofia B. Rodriguez, Chan Sun Park, Sean M. Cahill, Richard B. Silverman, Thomas S. Leyh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Diphosphomevalonate (Mev·pp) is the founding member of a new class of potential antibiotics targeting the Streptococcus pneumoniae mevalonate (Mev) pathway. We have synthesized a series of Mev·pp analogues designed to simultaneously block two steps in this pathway, through allosteric inhibition of mevalonate kinase (MK) and, for five of the analogues, by mechanismbased inactivation of diphosphomevalonate decarboxylase (DPM-DC). The analogue series expands the C3-methyl group of Mev·pp with hydrocarbons of varying size, shape, and chemical and physical properties. Previously, we established the feasibility of a prodrug strategy in which unphosphorylated Mev analogues could be enzymatically converted to the active Mev·pp forms by the endogenous MK and phosphomevalonate kinase.Wenowreport the kinetic parameters for the turnover of non-, mono-, and diphosphorylated analogues as substrates and inhibitors of the three mevalonate pathway enzymes. The inhibition of MK by Mev·pp analogues revealed that the allosteric site is selective for compact, electron-rich C3-subsitutents. The lack of reactivity of analogues with DPM-DC provided evidence, counter to the existing model, for a decarboxylation transition state that is concerted rather than dissociative. The Mev pathway is composed of three structurally and functionally conserved enzymes that catalyze consecutive steps in a metabolic pathway. The current work reveals that these enzymes exhibit significant differences in specificity toward R-group substitution at C3 and that these patterns are explained well by changes in the volume of the C3 R-group-binding pockets of the enzymes.

Original languageEnglish (US)
Pages (from-to)20654-20663
Number of pages10
JournalJournal of Biological Chemistry
Volume285
Issue number27
DOIs
StatePublished - Jul 2 2010

Fingerprint

mevalonate kinase
Mevalonic Acid
pyrophosphomevalonate decarboxylase
Streptococcus pneumoniae
Ligands
Enzymes
Allosteric Site
Decarboxylation
Prodrugs
Hydrocarbons
Metabolic Networks and Pathways
Kinetic parameters
Chemical properties
Substitution reactions
Physical properties
Electrons
Anti-Bacterial Agents
Substrates

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Probing ligand-binding pockets of the mevalonate pathway enzymes from Streptococcus pneumoniae. / Lefurgy, Scott T.; Rodriguez, Sofia B.; Park, Chan Sun; Cahill, Sean M.; Silverman, Richard B.; Leyh, Thomas S.

In: Journal of Biological Chemistry, Vol. 285, No. 27, 02.07.2010, p. 20654-20663.

Research output: Contribution to journalArticle

Lefurgy, Scott T. ; Rodriguez, Sofia B. ; Park, Chan Sun ; Cahill, Sean M. ; Silverman, Richard B. ; Leyh, Thomas S. / Probing ligand-binding pockets of the mevalonate pathway enzymes from Streptococcus pneumoniae. In: Journal of Biological Chemistry. 2010 ; Vol. 285, No. 27. pp. 20654-20663.
@article{6c1f05f2c2c5420fba8997f7314c92fd,
title = "Probing ligand-binding pockets of the mevalonate pathway enzymes from Streptococcus pneumoniae",
abstract = "Diphosphomevalonate (Mev·pp) is the founding member of a new class of potential antibiotics targeting the Streptococcus pneumoniae mevalonate (Mev) pathway. We have synthesized a series of Mev·pp analogues designed to simultaneously block two steps in this pathway, through allosteric inhibition of mevalonate kinase (MK) and, for five of the analogues, by mechanismbased inactivation of diphosphomevalonate decarboxylase (DPM-DC). The analogue series expands the C3-methyl group of Mev·pp with hydrocarbons of varying size, shape, and chemical and physical properties. Previously, we established the feasibility of a prodrug strategy in which unphosphorylated Mev analogues could be enzymatically converted to the active Mev·pp forms by the endogenous MK and phosphomevalonate kinase.Wenowreport the kinetic parameters for the turnover of non-, mono-, and diphosphorylated analogues as substrates and inhibitors of the three mevalonate pathway enzymes. The inhibition of MK by Mev·pp analogues revealed that the allosteric site is selective for compact, electron-rich C3-subsitutents. The lack of reactivity of analogues with DPM-DC provided evidence, counter to the existing model, for a decarboxylation transition state that is concerted rather than dissociative. The Mev pathway is composed of three structurally and functionally conserved enzymes that catalyze consecutive steps in a metabolic pathway. The current work reveals that these enzymes exhibit significant differences in specificity toward R-group substitution at C3 and that these patterns are explained well by changes in the volume of the C3 R-group-binding pockets of the enzymes.",
author = "Lefurgy, {Scott T.} and Rodriguez, {Sofia B.} and Park, {Chan Sun} and Cahill, {Sean M.} and Silverman, {Richard B.} and Leyh, {Thomas S.}",
year = "2010",
month = "7",
day = "2",
doi = "10.1074/jbc.M109.098350",
language = "English (US)",
volume = "285",
pages = "20654--20663",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "27",

}

TY - JOUR

T1 - Probing ligand-binding pockets of the mevalonate pathway enzymes from Streptococcus pneumoniae

AU - Lefurgy, Scott T.

AU - Rodriguez, Sofia B.

AU - Park, Chan Sun

AU - Cahill, Sean M.

AU - Silverman, Richard B.

AU - Leyh, Thomas S.

PY - 2010/7/2

Y1 - 2010/7/2

N2 - Diphosphomevalonate (Mev·pp) is the founding member of a new class of potential antibiotics targeting the Streptococcus pneumoniae mevalonate (Mev) pathway. We have synthesized a series of Mev·pp analogues designed to simultaneously block two steps in this pathway, through allosteric inhibition of mevalonate kinase (MK) and, for five of the analogues, by mechanismbased inactivation of diphosphomevalonate decarboxylase (DPM-DC). The analogue series expands the C3-methyl group of Mev·pp with hydrocarbons of varying size, shape, and chemical and physical properties. Previously, we established the feasibility of a prodrug strategy in which unphosphorylated Mev analogues could be enzymatically converted to the active Mev·pp forms by the endogenous MK and phosphomevalonate kinase.Wenowreport the kinetic parameters for the turnover of non-, mono-, and diphosphorylated analogues as substrates and inhibitors of the three mevalonate pathway enzymes. The inhibition of MK by Mev·pp analogues revealed that the allosteric site is selective for compact, electron-rich C3-subsitutents. The lack of reactivity of analogues with DPM-DC provided evidence, counter to the existing model, for a decarboxylation transition state that is concerted rather than dissociative. The Mev pathway is composed of three structurally and functionally conserved enzymes that catalyze consecutive steps in a metabolic pathway. The current work reveals that these enzymes exhibit significant differences in specificity toward R-group substitution at C3 and that these patterns are explained well by changes in the volume of the C3 R-group-binding pockets of the enzymes.

AB - Diphosphomevalonate (Mev·pp) is the founding member of a new class of potential antibiotics targeting the Streptococcus pneumoniae mevalonate (Mev) pathway. We have synthesized a series of Mev·pp analogues designed to simultaneously block two steps in this pathway, through allosteric inhibition of mevalonate kinase (MK) and, for five of the analogues, by mechanismbased inactivation of diphosphomevalonate decarboxylase (DPM-DC). The analogue series expands the C3-methyl group of Mev·pp with hydrocarbons of varying size, shape, and chemical and physical properties. Previously, we established the feasibility of a prodrug strategy in which unphosphorylated Mev analogues could be enzymatically converted to the active Mev·pp forms by the endogenous MK and phosphomevalonate kinase.Wenowreport the kinetic parameters for the turnover of non-, mono-, and diphosphorylated analogues as substrates and inhibitors of the three mevalonate pathway enzymes. The inhibition of MK by Mev·pp analogues revealed that the allosteric site is selective for compact, electron-rich C3-subsitutents. The lack of reactivity of analogues with DPM-DC provided evidence, counter to the existing model, for a decarboxylation transition state that is concerted rather than dissociative. The Mev pathway is composed of three structurally and functionally conserved enzymes that catalyze consecutive steps in a metabolic pathway. The current work reveals that these enzymes exhibit significant differences in specificity toward R-group substitution at C3 and that these patterns are explained well by changes in the volume of the C3 R-group-binding pockets of the enzymes.

UR - http://www.scopus.com/inward/record.url?scp=77954223261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954223261&partnerID=8YFLogxK

U2 - 10.1074/jbc.M109.098350

DO - 10.1074/jbc.M109.098350

M3 - Article

C2 - 20404339

AN - SCOPUS:77954223261

VL - 285

SP - 20654

EP - 20663

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 27

ER -